Cencora, Inc.

NYSE:COR

Medical - Distribution

Healthcare
$348.31 -2.04%

-$5.65 today

Market cap
$66.47B
Beta
0.59
P/E (TTM)
20.7
EPS (TTM)
$13.10
Dividend yield
0.87%
52W Low $244.82High $377.54

Volume 1.20M

Average 1.78M

COR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Cencora, Inc.NYSE: COR

Gross Profit · Q3 FY2026 · quarter ended Jun 2026

Gross profit growth accelerates

Q3 FY2026 gross profit of $3.61B rose 35.7% year over year, ahead of the +27.3% change in trailing-twelve-month gross profit. Sequentially, it rose 8.6% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.

Context

  • Gross profit amounted to 3.2% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +35.7% holds above the trailing-twelve-month pace of +27.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.61B+8.6% QoQ
Last fiscal yearSep 2025
$10.14B+16.6% YoY
LTMJun 2026
$12.34B+27.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.7%——
1 year+16.6%——
3-year CAGR+10.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
10.14B USD
Year-over-year change
+16.6%
4-year CAGR
+12.8%

Gross Profit vs competitors

How COR compares with its peers on the latest reported figures

  • COR's LTM Jun 2026 gross profit of $12.34B is the 2nd highest of the 5 companies compared; the peer median is $7.09B.
  • Its year-over-year change of +27.3% is the highest of 5, against a peer median of +13.5%.
  • Gross profit amounts to 3.7% of revenue for COR, versus a peer median of 17.1%.
COR Competitors Peer median
Gross Profit for COR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCKMcKesson CorporationLTM Jun 2026$14.96B +19.0%+7.0%3.6%
CORCencora, Inc.LTM Jun 2026$12.34B +27.3%+10.1%3.7%
CAHCardinal Health, Inc.LTM Sep 2026$10.05B +17.1%+12.4%3.9%
HSICHenry Schein, Inc.LTM Jun 2026$4.12B +10.0%+1.7%30.3%
ACHAccendra Health, Inc.LTM Mar 2026$1.12B -36.0%-13.0%41.3%
Peer median (excluding COR) $7.09B+13.5%+4.4%17.1%

Competitors are the stored peer set for COR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue213.99B238.59B262.17B293.96B321.33B
Cost of Revenue207.72B230.99B254.42B285.26B311.19B
Gross Profit6.27B7.6B7.76B8.7B10.14B
Gross Margin2.9%3.2%3.0%3.0%3.2%
Research & Development00000
Selling, General & Admin3.59B4.85B5.31B5.66B6.49B
Operating Expenses3.59B4.85B5.31B5.66B6.49B
Depreciation & Amortization514.79M709.84M980.85M1.12B1.07B
EBITDA2.92B3.12B3.42B3.37B3.75B
EBITDA Margin1.4%1.3%1.3%1.1%1.2%
Operating Income2.68B2.75B2.45B3.04B3.65B
Operating Margin1.3%1.2%0.9%1.0%1.1%
Interest Income8.47M21.31M46.72M91.69M128.21M
Interest Expense182.54M231.98M275.65M248.68M419.75M
Other Income / Expenses(453.15M)(568.62M)(285.68M)(1.04B)(1.39B)
Income Before Tax2.22B2.18B2.16B2B2.26B
Pre-Tax Margin1.0%0.9%0.8%0.7%0.7%
Income Tax Expense677.25M516.52M428.26M484.7M690.52M
Net Income1.54B1.7B1.75B1.51B1.55B
Net Margin0.7%0.7%0.7%0.5%0.5%
EPS (Basic)7.488.158.627.608.02
EPS (Diluted)7.398.048.537.537.96
Weighted Avg Shares205.92M208.47M204.59M198.5M193.82M
Weighted Avg Shares (Diluted)208.47M211.21M204.59M200.28M195.21M

Cencora, Inc.

NYSE:COR

Intrinsic Alpha fair value

Locked

Current Price

$348.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.